Literature DB >> 32535743

Feasibility study of a PET-only amyloid quantification method: a comparison with visual interpretation.

Natsumi Shimokawa1, Go Akamatsu2, Miyako Kadosaki3,4, Masayuki Sasaki5.   

Abstract

OBJECTIVE: Visual evaluation is the standard for amyloid positron emission tomography (PET) examination, though the result depends upon the physician's subjective review of the images. Therefore, it is expected that objective quantitative evaluation is useful for image interpretation. In this study, we examined the usefulness of the quantitative evaluation of amyloid PET using a PET-only quantification method in comparison with visual evaluation.
METHODS: In this study we retrospectively investigated a total of 166 individuals, including 58 cognitively normal controls, 62 individuals with mild cognitive impairment, and 46 individuals with early Alzheimer's disease. They underwent 11C-Pittsburgh compound-B (PiB) PET examination through the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI). Amyloid accumulation in cerebral cortices was assessed using visual and quantitative methods. The quantitative evaluation was performed using the adaptive template method and empirically PiB-prone region of interest, and the standardized uptake value ratio (SUVR) in each area was obtained.
RESULTS: Visual evaluation and SUVR were significantly correlated in the cerebral cortices (ρ = 0.85-0.87; p < 0.05). In visual evaluation, sensitivity, specificity, and accuracy were 78%, 76%, and 77%, respectively. Meanwhile, for quantitative evaluation, sensitivity, specificity, and accuracy were 77%, 79%, and 78% in mean cortical SUVR (mcSUVR) and 79%, 79%, and 79% in maximum SUVR (maxSUVR), respectively.
CONCLUSION: The PET-only quantification method provided a concordant result with visual evaluation and was considered useful for amyloid PET.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid PET; Quantitative evaluation; Visual evaluation

Mesh:

Substances:

Year:  2020        PMID: 32535743     DOI: 10.1007/s12149-020-01486-3

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  20 in total

Review 1.  Acetylcholinesterase inhibitors in Alzheimer's disease.

Authors:  B M McGleenon; K B Dynan; A P Passmore
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

2.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

Authors:  Brian J Lopresti; William E Klunk; Chester A Mathis; Jessica A Hoge; Scott K Ziolko; Xueling Lu; Carolyn C Meltzer; Kurt Schimmel; Nicholas D Tsopelas; Steven T DeKosky; Julie C Price
Journal:  J Nucl Med       Date:  2005-12       Impact factor: 10.057

3.  [Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD)].

Authors:  Toshiharu Ninomiya
Journal:  Brain Nerve       Date:  2017-07

4.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.

Authors:  Osama Sabri; Marwan N Sabbagh; John Seibyl; Henryk Barthel; Hiroyasu Akatsu; Yasuomi Ouchi; Kohei Senda; Shigeo Murayama; Kenji Ishii; Masaki Takao; Thomas G Beach; Christopher C Rowe; James B Leverenz; Bernardino Ghetti; James W Ironside; Ana M Catafau; Andrew W Stephens; Andre Mueller; Norman Koglin; Anja Hoffmann; Katrin Roth; Cornelia Reininger; Walter J Schulz-Schaeffer
Journal:  Alzheimers Dement       Date:  2015-03-28       Impact factor: 21.566

5.  Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.

Authors:  Craig Curtis; Jose E Gamez; Upinder Singh; Carl H Sadowsky; Teresa Villena; Marwan N Sabbagh; Thomas G Beach; Ranjan Duara; Adam S Fleisher; Kirk A Frey; Zuzana Walker; Arvinder Hunjan; Clive Holmes; Yavir M Escovar; Carla X Vera; Marc E Agronin; Joel Ross; Andrea Bozoki; Mary Akinola; Jiong Shi; Rik Vandenberghe; Milos D Ikonomovic; Paul F Sherwin; Igor D Grachev; Gillian Farrar; Adrian P L Smith; Christopher J Buckley; Richard McLain; Stephen Salloway
Journal:  JAMA Neurol       Date:  2015-03       Impact factor: 18.302

6.  11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Authors:  Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman
Journal:  Lancet Neurol       Date:  2010-02-26       Impact factor: 44.182

7.  Subtype analysis of neuropathologically diagnosed patients in a Japanese geriatric hospital.

Authors:  Hiroyasu Akatsu; Mitsuo Takahashi; Noriyuki Matsukawa; Yasushige Ishikawa; Naoki Kondo; Tomoo Sato; Hideka Nakazawa; Tatsuo Yamada; Hidechika Okada; Takayuki Yamamoto; Kenji Kosaka
Journal:  J Neurol Sci       Date:  2002-04-15       Impact factor: 3.181

8.  Use of florbetapir-PET for imaging beta-amyloid pathology.

Authors:  Christopher M Clark; Julie A Schneider; Barry J Bedell; Thomas G Beach; Warren B Bilker; Mark A Mintun; Michael J Pontecorvo; Franz Hefti; Alan P Carpenter; Matthew L Flitter; Michael J Krautkramer; Hank F Kung; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Marwan N Sabbagh; Carl H Sadowsky; Eric P Reiman; P Eric M Reiman; Simone P Zehntner; Daniel M Skovronsky
Journal:  JAMA       Date:  2011-01-19       Impact factor: 56.272

9.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

Authors:  Christopher M Clark; Michael J Pontecorvo; Thomas G Beach; Barry J Bedell; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Eric M Reiman; Marwan N Sabbagh; Carl H Sadowsky; Julie A Schneider; Anupa Arora; Alan P Carpenter; Matthew L Flitter; Abhinay D Joshi; Michael J Krautkramer; Ming Lu; Mark A Mintun; Daniel M Skovronsky
Journal:  Lancet Neurol       Date:  2012-06-28       Impact factor: 44.182

10.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Authors:  Randall J Bateman; Chengjie Xiong; Tammie L S Benzinger; Anne M Fagan; Alison Goate; Nick C Fox; Daniel S Marcus; Nigel J Cairns; Xianyun Xie; Tyler M Blazey; David M Holtzman; Anna Santacruz; Virginia Buckles; Angela Oliver; Krista Moulder; Paul S Aisen; Bernardino Ghetti; William E Klunk; Eric McDade; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Peter R Schofield; Reisa A Sperling; Stephen Salloway; John C Morris
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

View more
  3 in total

1.  Improved Accuracy of Amyloid PET Quantification with Adaptive Template-Based Anatomic Standardization.

Authors:  Yuma Tsubaki; Takayoshi Kitamura; Natsumi Shimokawa; Go Akamatsu; Masayuki Sasaki
Journal:  J Nucl Med Technol       Date:  2021-04-05

Review 2.  Protein Biomarkers for the Diagnosis of Alzheimer's Disease at Different Stages of Neurodegeneration.

Authors:  Mar Pérez; Félix Hernández; Jesús Avila
Journal:  Int J Mol Sci       Date:  2020-09-15       Impact factor: 5.923

3.  Longitudinal change in ATN biomarkers in cognitively normal individuals.

Authors:  Jarith L Ebenau; Denise Visser; Lior A Kroeze; Mardou S S A van Leeuwenstijn; Argonde C van Harten; Albert D Windhorst; Sandeep V S Golla; Ronald Boellaard; Philip Scheltens; Frederik Barkhof; Bart N M van Berckel; Wiesje M van der Flier
Journal:  Alzheimers Res Ther       Date:  2022-09-03       Impact factor: 8.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.